

28 August 2023

The Manager-Listings
Australian Securities Exchange Limited
Exchange Centre
20 Bridge Street
Sydney NSW 2000

Via Electronic lodgement


Dear Sir

Appendix 4E and 2023 Directors' Report and Financial Statements

Pharmaxis Ltd lodges the following documents in relation to its announcement to the market of its financial results for the year ended 30 June 2023.

1. Appendix 4E – Preliminary Final Report for the year ended 30 June 2023;
and
2. Pharmaxis 2023 Directors' Report and Annual Financial Report for the
year ended 30 June 2023.

Yours faithfully



David McGarvey
Pharmaxis Ltd
Chief Financial Officer / Company Secretary

Pharmaxis Ltd
ABN 75 082 811 630

Appendix 4E
Preliminary final report
Reporting period: Year ended 30th June 2023
(Previous corresponding period: Year ended 30th June 2022)

Results for announcement to the market

		<u>A\$'000</u>		<u>A\$'000</u>
Revenue from sale of goods	Down	(1,661)	to	5,765
Other revenue from ordinary activities	Up	4,813	to	7,309
Total revenue from ordinary activities	Up	<u>3,394</u>	to	<u>19,306</u>
Loss from ordinary activities after tax	Up	(9,424)	to	(11,360)
Net loss for the year attributable to members	Up	(9,424)	to	(11,360)

Dividends

It is not proposed to pay a dividend.

Other Appendix 4E information

	<u>30 June</u> <u>2023</u>	<u>30 June</u> <u>2022</u>
Net tangible assets per ordinary share	\$ 0.01	\$ 0.02

A commentary on these results and additional Appendix 4E disclosure requirements can be found in the attached Pharmaxis 2023 Directors' Report and Annual Financial Report. This report is based on the consolidated financial statements which have been audited by PwC.